Who
Phuong Khanh Morrow
Director
Company insider
Files Form 4 as: Director, Lantheus Holdings; Chief Medical Officer, CRISPR Therapeutics AG.
In numbers
- Trades disclosed
- 16
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 23 May 2022
- Last trade
- 14 May 2026
- Last filed
- 18 May 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 May 2026filed 18 May 2026 | LNTH Lantheus HoldingsDiagnostics & Labs | SEC FORM 4 Code A | —4,137 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | LNTH Lantheus HoldingsDiagnostics & Labs | SEC FORM 4 Code A | —4,137 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | LNTH Lantheus Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —4,543 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | LNTH Lantheus HoldingsDiagnostics & Labs | SEC FORM 4 Code A | —2,537 at $0.00 | filing |
| 7 Feb 2025filed 12 Feb 2025 | LNTH Lantheus Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —1,015 at $0.00 | filing |
| 7 Feb 2025filed 11 Feb 2025 | LNTH Lantheus Holdingsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —1,017 at $0.00 | filing |
| 7 Feb 2025filed 11 Feb 2025 | LNTH Lantheus HoldingsDiagnostics & Labs | SEC FORM 4 Code A | —563 at $0.00 | filing |
| 13 Oct 2023filed 17 Oct 2023 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —16,667 at $0.00 | filing |
| 24 May 2023filed 25 May 2023 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code F | $167K2,527 at $65.91 | filing |
| 23 May 2023filed 25 May 2023 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —6,938 | filing |
| 23 May 2023filed 25 May 2023 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Code M | —6,938 | filing |
| 10 Mar 2023filed 14 Mar 2023 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —44,620 at $0.00 | filing |
| 10 Mar 2023filed 14 Mar 2023 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 7 Oct 2022filed 12 Oct 2022 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —9,380 at $0.00 | filing |
| 23 May 2022filed 24 May 2022 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —27,750 at $0.00 | filing |
| 23 May 2022filed 24 May 2022 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.